Abida Parveen
Research Subjects
Abida Parveen has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
Ali Karim
Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan
3 shared publications- Ali Karim
Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
3 shared publications - Jahanzeb Malik
Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan
3 shared publications Ali Umair
Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan
2 shared publicationsFnu Arti
Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan
2 shared publicationsFnu Neelam
Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan
2 shared publications
Latest Publications
- Open Access
- 3 April 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105  (14) , e46522
Outcomes and predictors of atrial fibrillation in cardiac amyloidosis
: Cardiac amyloidosis (CA) frequently coexists with atrial fibrillation (AF), but the extent and impact of this relationship remain unclear. This study investigates the prevalence of AF in CA, compares clinical characteristics between amyloid light-chain (AL)-CA and amyloid transthyretin (ATTR)-CA, and assesses the implications for treatment strategies. We conducted a retrospective analysis of 108 patients with confirmed CA, categorizing them into 2 groups: 51 with AF and 57 with sinus rhythm (SR). We compared demographic, clinical, and echocardiographic data, as well as treatment modalities and outcomes between AL-CA and ATTR-CA subgroups. AF was present in 47% of the cohort, with a notably higher prevalence in wild-type ATTR-CA (80%) compared to AL-CA (33%). Patients with AF were older (73.8 ± 8.5 years) than those with SR (67.7 ± 10.6 years, P < .001) and had more severe heart failure symptoms, comorbidities, and echocardiographic abnormalities, including reduced left ventricular ejection fraction (LVEF; 47% vs 53%, P = .003) and higher pulmonary artery pressures (41 ± 11 mm Hg vs 35 ± 17 mm Hg, P = .02). Logistic regression identified BMI (OR 1.2, 95% CI: 1.05–1.57, P = .02) and eGFR (OR 0.91, 95% CI: 0.92–0.99, P = .04) as independent predictors of AF. CHA2DS2-VASc scores were higher in ATTR-CA patients (4.5 ± 1.2) compared to AL-CA (2.4 ± 1.1, P < .001). Despite a high rate of anticoagulation (78%), ischemic stroke or TIA incidence was low at 6% over 12 months. AF is highly prevalent in CA, particularly in ATTR-CA, and is associated with more severe clinical manifestations. The findings highlight the necessity for systematic AF screening and tailored management strategies in CA patients. Prospective, randomized studies are essential to establish optimal AF treatment protocols in this population.
- 3 April 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105  (14) , e46522
Open AccessOutcomes and predictors of atrial fibrillation in cardiac amyloidosis
: Cardiac amyloidosis (CA) frequently coexists with atrial fibrillation (AF), but the extent and impact of this relationship remain unclear. This study investigates the prevalence of AF in CA, compares clinical characteristics between amyloid light-chain (AL)-CA and amyloid transthyretin (ATTR)-CA, and assesses the implications for treatment strategies. We conducted a retrospective analysis of 108 patients with confirmed CA, categorizing them into 2 groups: 51 with AF and 57 with sinus rhythm (SR). We compared demographic, clinical, and echocardiographic data, as well as treatment modalities and outcomes between AL-CA and ATTR-CA subgroups. AF was present in 47% of the cohort, with a notably higher prevalence in wild-type ATTR-CA (80%) compared to AL-CA (33%). Patients with AF were older (73.8 ± 8.5 years) than those with SR (67.7 ± 10.6 years, P < .001) and had more severe heart failure symptoms, comorbidities, and echocardiographic abnormalities, including reduced left ventricular ejection fraction (LVEF; 47% vs 53%, P = .003) and higher pulmonary artery pressures (41 ± 11 mm Hg vs 35 ± 17 mm Hg, P = .02). Logistic regression identified BMI (OR 1.2, 95% CI: 1.05–1.57, P = .02) and eGFR (OR 0.91, 95% CI: 0.92–0.99, P = .04) as independent predictors of AF. CHA2DS2-VASc scores were higher in ATTR-CA patients (4.5 ± 1.2) compared to AL-CA (2.4 ± 1.1, P < .001). Despite a high rate of anticoagulation (78%), ischemic stroke or TIA incidence was low at 6% over 12 months. AF is highly prevalent in CA, particularly in ATTR-CA, and is associated with more severe clinical manifestations. The findings highlight the necessity for systematic AF screening and tailored management strategies in CA patients. Prospective, randomized studies are essential to establish optimal AF treatment protocols in this population.
- Open Access
- 30 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105  (5) , e44491
Advantages of skeletonizing the left colic artery in low anterior resection cases related to vascularity with ICG: A systematic review
Background: LAR for rectal cancer requires optimal bowel perfusion to minimize AL, a serious postoperative complication. Preservation of the left colic artery (LCA) through skeletonization may improve vascular supply. Indocyanine green (ICG) fluorescence imaging is increasingly utilized intraoperatively to assess real-time bowel perfusion and guide surgical decisions. Methods: A systematic review was conducted following PRISMA guidelines. Databases including PubMed, Scopus, Web of Science, and Embase were searched up to May 2025. Studies evaluating intraoperative ICG fluorescence imaging in colorectal cancer surgery with outcomes related to AL, lymph node yield, or recurrence were included. Both randomized and observational studies were considered. Quality was assessed using the Newcastle-Ottawa Scale, and a qualitative synthesis was performed. Results: Nine studies involving 1771 patients met inclusion criteria. ICG fluorescence imaging consistently improved intraoperative assessment of bowel perfusion, influencing surgical decision-making and reducing AL rates, particularly when combined with LCA skeletonization. Preservation of the LCA was associated with enhanced vascular integrity and comparable lymph node yields. Studies reported an AL reduction from approximately 10% to below 5% with ICG guidance. ICG also aided in optimizing transection lines and improved lymphadenectomy precision. Conclusion: ICG fluorescence imaging, combined with LCA skeletonization, appears to enhance bowel perfusion assessment and reduce anastomotic complications in LAR for colorectal cancer. While promising, further randomized controlled trials are needed to confirm long-term oncologic outcomes and establish standardized protocols.
- 30 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105  (5) , e44491
Open AccessAdvantages of skeletonizing the left colic artery in low anterior resection cases related to vascularity with ICG: A systematic review
Background: LAR for rectal cancer requires optimal bowel perfusion to minimize AL, a serious postoperative complication. Preservation of the left colic artery (LCA) through skeletonization may improve vascular supply. Indocyanine green (ICG) fluorescence imaging is increasingly utilized intraoperatively to assess real-time bowel perfusion and guide surgical decisions. Methods: A systematic review was conducted following PRISMA guidelines. Databases including PubMed, Scopus, Web of Science, and Embase were searched up to May 2025. Studies evaluating intraoperative ICG fluorescence imaging in colorectal cancer surgery with outcomes related to AL, lymph node yield, or recurrence were included. Both randomized and observational studies were considered. Quality was assessed using the Newcastle-Ottawa Scale, and a qualitative synthesis was performed. Results: Nine studies involving 1771 patients met inclusion criteria. ICG fluorescence imaging consistently improved intraoperative assessment of bowel perfusion, influencing surgical decision-making and reducing AL rates, particularly when combined with LCA skeletonization. Preservation of the LCA was associated with enhanced vascular integrity and comparable lymph node yields. Studies reported an AL reduction from approximately 10% to below 5% with ICG guidance. ICG also aided in optimizing transection lines and improved lymphadenectomy precision. Conclusion: ICG fluorescence imaging, combined with LCA skeletonization, appears to enhance bowel perfusion assessment and reduce anastomotic complications in LAR for colorectal cancer. While promising, further randomized controlled trials are needed to confirm long-term oncologic outcomes and establish standardized protocols.
- Open Access
- 2 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105  (1) , e46824
Clinical outcomes associated with failed thrombus aspiration during primary percutaneous coronary intervention
Thrombus aspiration is performed during primary percutaneous coronary intervention (PCI) to improve outcomes in patients with ST-elevation myocardial infarction (STEMI). However, its success varies, and failed aspiration may impact prognosis. This study aimed to determine the predictors and clinical outcomes associated with failed thrombus aspiration. This retrospective study included 5323 patients who underwent primary PCI for STEMI. Patients were categorized into failed and successful thrombus aspiration groups. Baseline characteristics, angiographic findings, and procedural details were compared. Multivariate logistic regression identified independent predictors of aspiration failure, and clinical outcomes were analyzed over one-year. Failed thrombus aspiration occurred in 1176 patients (22.1%). Independent predictors included age ≥ 65 years, diabetes, hypertension, multi-vessel disease, high thrombus burden, and longer fluoroscopy time (all P < .001). Patients with failed aspiration had significantly higher in-hospital mortality (13.9% vs 5.6%), no-reflow (35.3% vs 6.5%), cardiogenic shock, and major adverse cardiovascular events (all P < .001). One-year mortality and heart failure hospitalizations were also increased. Failed thrombus aspiration is associated with worse short- and long-term outcomes in STEMI patients undergoing primary PCI. Identifying high-risk patients may help optimize procedural strategies and improve outcomes.
- 2 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105  (1) , e46824
Open AccessClinical outcomes associated with failed thrombus aspiration during primary percutaneous coronary intervention
Thrombus aspiration is performed during primary percutaneous coronary intervention (PCI) to improve outcomes in patients with ST-elevation myocardial infarction (STEMI). However, its success varies, and failed aspiration may impact prognosis. This study aimed to determine the predictors and clinical outcomes associated with failed thrombus aspiration. This retrospective study included 5323 patients who underwent primary PCI for STEMI. Patients were categorized into failed and successful thrombus aspiration groups. Baseline characteristics, angiographic findings, and procedural details were compared. Multivariate logistic regression identified independent predictors of aspiration failure, and clinical outcomes were analyzed over one-year. Failed thrombus aspiration occurred in 1176 patients (22.1%). Independent predictors included age ≥ 65 years, diabetes, hypertension, multi-vessel disease, high thrombus burden, and longer fluoroscopy time (all P < .001). Patients with failed aspiration had significantly higher in-hospital mortality (13.9% vs 5.6%), no-reflow (35.3% vs 6.5%), cardiogenic shock, and major adverse cardiovascular events (all P < .001). One-year mortality and heart failure hospitalizations were also increased. Failed thrombus aspiration is associated with worse short- and long-term outcomes in STEMI patients undergoing primary PCI. Identifying high-risk patients may help optimize procedural strategies and improve outcomes.
- Open Access
- 5 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104  (49) , e46189
Chronic kidney disease and cardiovascular risk: Pathophysiology and interventional approaches – systematic review
Background: Chronic kidney disease (CKD) is a major public health concern due to its association with increased cardiovascular risk. Patients with CKD, especially those with moderate to severe renal dysfunction, face a heightened risk of cardiovascular events and mortality. This systematic review evaluates the relationship between CKD and cardiovascular risk, focusing on the pathophysiology, risk factors, and clinical outcomes related to cardiovascular disease (CVD) in CKD populations. Methods: A comprehensive search of electronic databases was conducted for studies investigating CKD and cardiovascular risk. Seven studies, including cross-sectional, and cohort designs, were included in this review. These studies involved a total of 104,576 participants, with diverse stages of CKD and varying cardiovascular risk profiles. Data on renal dysfunction stages, cardiovascular risk factors, and mortality outcomes were extracted and analyzed. Results: The studies consistently demonstrated that CKD is associated with an increased risk of cardiovascular events, including coronary heart disease and stroke, compared to individuals without CKD. Even early stages of CKD were linked to a higher likelihood of CVD. Participants with CKD exhibited a greater burden of traditional cardiovascular risk factors, including hypertension, diabetes, dyslipidemia, and obesity. The overall mortality rate from cardiovascular causes was also higher in CKD patients, with some studies reporting a two-fold or greater increase in risk. Conclusion: CKD is strongly linked to an increased cardiovascular risk, with higher stages of renal dysfunction associated with a more significant risk of cardiovascular morbidity and mortality. This review emphasizes the need for early detection and comprehensive management of cardiovascular risk factors in CKD patients. Future research should focus on identifying novel biomarkers and evaluating the long-term efficacy of emerging therapies in reducing cardiovascular risk in CKD populations.
- 5 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104  (49) , e46189
Open AccessChronic kidney disease and cardiovascular risk: Pathophysiology and interventional approaches – systematic review
Background: Chronic kidney disease (CKD) is a major public health concern due to its association with increased cardiovascular risk. Patients with CKD, especially those with moderate to severe renal dysfunction, face a heightened risk of cardiovascular events and mortality. This systematic review evaluates the relationship between CKD and cardiovascular risk, focusing on the pathophysiology, risk factors, and clinical outcomes related to cardiovascular disease (CVD) in CKD populations. Methods: A comprehensive search of electronic databases was conducted for studies investigating CKD and cardiovascular risk. Seven studies, including cross-sectional, and cohort designs, were included in this review. These studies involved a total of 104,576 participants, with diverse stages of CKD and varying cardiovascular risk profiles. Data on renal dysfunction stages, cardiovascular risk factors, and mortality outcomes were extracted and analyzed. Results: The studies consistently demonstrated that CKD is associated with an increased risk of cardiovascular events, including coronary heart disease and stroke, compared to individuals without CKD. Even early stages of CKD were linked to a higher likelihood of CVD. Participants with CKD exhibited a greater burden of traditional cardiovascular risk factors, including hypertension, diabetes, dyslipidemia, and obesity. The overall mortality rate from cardiovascular causes was also higher in CKD patients, with some studies reporting a two-fold or greater increase in risk. Conclusion: CKD is strongly linked to an increased cardiovascular risk, with higher stages of renal dysfunction associated with a more significant risk of cardiovascular morbidity and mortality. This review emphasizes the need for early detection and comprehensive management of cardiovascular risk factors in CKD patients. Future research should focus on identifying novel biomarkers and evaluating the long-term efficacy of emerging therapies in reducing cardiovascular risk in CKD populations.
- Open Access
- 28 November 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104  (48) , e46239
Exosomal miRNAs versus circulating tumor DNA: diagnostic accuracy for early detection of recurrence post-radical prostatectomy: A narrative review
Prostate cancer is a leading malignancy worldwide, and while radical prostatectomy is an effective treatment for localized disease, a significant proportion of patients experience biochemical recurrence. Prostate-specific antigen (PSA) remains the primary biomarker for recurrence detection, but its limitations in specificity necessitate improved surveillance tools. Liquid biopsy techniques, particularly exosomal microRNAs (miRNAs) and circulating tumor DNA (ctDNA), have emerged as promising noninvasive biomarkers for early recurrence detection. However, their comparative diagnostic accuracy remains unclear. This narrative review explores the diagnostic potential of exosomal miRNAs and ctDNA for early recurrence detection following radical prostatectomy. It examines their biological characteristics, detection methodologies, comparative diagnostic performance, and clinical challenges. Both exosomal miRNAs and ctDNA hold significant potential for the early detection of prostate cancer recurrence post-radical prostatectomy. However, the lack of standardized protocols and the variability in current studies limit definitive conclusions about their relative accuracy. Future large-scale, prospective studies are necessary to validate their clinical utility and establish guidelines for their integration into routine surveillance. A multi-biomarker approach combining exosomal miRNAs, ctDNA, and PSA may provide the most effective strategy for personalized prostate cancer monitoring.
- 28 November 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104  (48) , e46239
Open AccessExosomal miRNAs versus circulating tumor DNA: diagnostic accuracy for early detection of recurrence post-radical prostatectomy: A narrative review
Prostate cancer is a leading malignancy worldwide, and while radical prostatectomy is an effective treatment for localized disease, a significant proportion of patients experience biochemical recurrence. Prostate-specific antigen (PSA) remains the primary biomarker for recurrence detection, but its limitations in specificity necessitate improved surveillance tools. Liquid biopsy techniques, particularly exosomal microRNAs (miRNAs) and circulating tumor DNA (ctDNA), have emerged as promising noninvasive biomarkers for early recurrence detection. However, their comparative diagnostic accuracy remains unclear. This narrative review explores the diagnostic potential of exosomal miRNAs and ctDNA for early recurrence detection following radical prostatectomy. It examines their biological characteristics, detection methodologies, comparative diagnostic performance, and clinical challenges. Both exosomal miRNAs and ctDNA hold significant potential for the early detection of prostate cancer recurrence post-radical prostatectomy. However, the lack of standardized protocols and the variability in current studies limit definitive conclusions about their relative accuracy. Future large-scale, prospective studies are necessary to validate their clinical utility and establish guidelines for their integration into routine surveillance. A multi-biomarker approach combining exosomal miRNAs, ctDNA, and PSA may provide the most effective strategy for personalized prostate cancer monitoring.
- Open Access
- 14 November 2025
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 15  (6) , 6-11
Quality of life changes post-PCI with contrast-induced nephropathy
Objective: This study aimed to evaluate the impact of contrast-induced nephropathy (CIN) on quality of life (QoL) in patients undergoing percutaneous coronary intervention (PCI) in Pakistan. Methods: A retrospective cohort study was conducted involving 5,325 patients who underwent PCI, divided into CIN (n = 1,250) and non-CIN (n = 4,075) groups. Demographics, clinical characteristics, and procedural details were recorded. QoL was assessed using a standardized questionnaire before and after PCI, covering physical functioning, pain, mobility, anxiety/depression, and overall health. Statistical analyses compared QoL scores between groups and identified predictors of change. Results: Patients who developed CIN exhibited a significant decline in post-PCI QoL across all domains compared to the non-CIN group (p < 0.05). CIN, older age, diabetes, lack of hydration protocol use, prolonged hospital stay, and lower baseline QoL were independent predictors of poorer QoL outcomes. Comorbidities were more prevalent in the CIN group, including diabetes (64.0% vs. 47.8%), hypertension (68.0% vs. 60.8%), and CKD Stage 3 or worse (28.0% vs. 8.6%) (all p < 0.05). CIN patients more frequently underwent PCI for acute coronary syndrome, received higher contrast volumes, and had lower use of preventive measures. Post-PCI complications such as heart failure (36.0%), dialysis requirement (32.0%), and prolonged hospital stays (60.0%) were significantly higher in CIN patients. Conclusion: CIN adversely affects QoL following PCI, particularly in high-risk patients. Preventive strategies and early intervention are essential to mitigate CIN-related complications and improve
- 14 November 2025
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 15  (6) , 6-11
Open AccessQuality of life changes post-PCI with contrast-induced nephropathy
Objective: This study aimed to evaluate the impact of contrast-induced nephropathy (CIN) on quality of life (QoL) in patients undergoing percutaneous coronary intervention (PCI) in Pakistan. Methods: A retrospective cohort study was conducted involving 5,325 patients who underwent PCI, divided into CIN (n = 1,250) and non-CIN (n = 4,075) groups. Demographics, clinical characteristics, and procedural details were recorded. QoL was assessed using a standardized questionnaire before and after PCI, covering physical functioning, pain, mobility, anxiety/depression, and overall health. Statistical analyses compared QoL scores between groups and identified predictors of change. Results: Patients who developed CIN exhibited a significant decline in post-PCI QoL across all domains compared to the non-CIN group (p < 0.05). CIN, older age, diabetes, lack of hydration protocol use, prolonged hospital stay, and lower baseline QoL were independent predictors of poorer QoL outcomes. Comorbidities were more prevalent in the CIN group, including diabetes (64.0% vs. 47.8%), hypertension (68.0% vs. 60.8%), and CKD Stage 3 or worse (28.0% vs. 8.6%) (all p < 0.05). CIN patients more frequently underwent PCI for acute coronary syndrome, received higher contrast volumes, and had lower use of preventive measures. Post-PCI complications such as heart failure (36.0%), dialysis requirement (32.0%), and prolonged hospital stays (60.0%) were significantly higher in CIN patients. Conclusion: CIN adversely affects QoL following PCI, particularly in high-risk patients. Preventive strategies and early intervention are essential to mitigate CIN-related complications and improve
- Open Access
- 14 November 2025
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 15  (6) , 18-24
Psychological impact of pulmonary embolism: A Narrative review.
Background: Pulmonary embolism (PE) is a potentially life-threatening thromboembolic condition that demands urgent medical attention. While significant strides have been made in the diagnosis, treatment, and prevention of PE, its long-term psychological consequences remain underexplored. Survivors often face considerable emotional and psychological challenges that can impair recovery and reduce quality of life. This narrative review aims to explore the psychological impact of PE, including common mental health outcomes such as anxiety, depression, post-traumatic stress disorder (PTSD), and health-related fears. It also examines contributing factors such as persistent physical symptoms, anticoagulation therapy, social and occupational disruptions, and gaps in mental health care within current clinical practice. PE is not solely a physical health event but a psychologically impactful experience with lasting consequences. Holistic management strategies that address both physical and emotional recovery are vital to improving long-term outcomes and quality of life in PE survivors.
- 14 November 2025
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 15  (6) , 18-24
Open AccessPsychological impact of pulmonary embolism: A Narrative review.
Background: Pulmonary embolism (PE) is a potentially life-threatening thromboembolic condition that demands urgent medical attention. While significant strides have been made in the diagnosis, treatment, and prevention of PE, its long-term psychological consequences remain underexplored. Survivors often face considerable emotional and psychological challenges that can impair recovery and reduce quality of life. This narrative review aims to explore the psychological impact of PE, including common mental health outcomes such as anxiety, depression, post-traumatic stress disorder (PTSD), and health-related fears. It also examines contributing factors such as persistent physical symptoms, anticoagulation therapy, social and occupational disruptions, and gaps in mental health care within current clinical practice. PE is not solely a physical health event but a psychologically impactful experience with lasting consequences. Holistic management strategies that address both physical and emotional recovery are vital to improving long-term outcomes and quality of life in PE survivors.
- Open Access
- 17 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104  (42) , e45175
Dysglycaemia and the risk of incident aortic valve disease: A population-based cohort study
This study evaluates the association between fasting glucose levels and the risk of incident aortic valve disease (AVD) in a large population-based cohort. This retrospective cohort study included 11,905 adults, excluding individuals with prior valve disease, missing data, or under 18 years of age. Participants were stratified by fasting glucose into low, normal, impaired fasting glucose (IFG), high glucose, and diagnosed diabetes categories. The primary outcome was incident AVD over long-term follow-up. Cox proportional hazards models adjusted for demographic and cardiovascular risk factors were used, supplemented by restricted cubic spline and age-stratified analyses. A total of 593 cases of AVD occurred among 11,905 participants during follow-up. IFG (hazard ratio 1.28, 95% confidence interval: 1.03–1.59) and diagnosed diabetes (hazard ratio 1.61, 95% confidence interval: 1.18–2.19) were significantly associated with increased risk. Spline analysis revealed a threshold effect above 5.5 mmol/L. Case–control comparisons showed persistently higher baseline glucose in cases. Kaplan–Meier curves demonstrated lowest event-free survival in diabetes and IFG groups. Even modest elevations in fasting glucose are associated with a significantly increased risk of AVD.
- 17 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104  (42) , e45175
Open AccessDysglycaemia and the risk of incident aortic valve disease: A population-based cohort study
This study evaluates the association between fasting glucose levels and the risk of incident aortic valve disease (AVD) in a large population-based cohort. This retrospective cohort study included 11,905 adults, excluding individuals with prior valve disease, missing data, or under 18 years of age. Participants were stratified by fasting glucose into low, normal, impaired fasting glucose (IFG), high glucose, and diagnosed diabetes categories. The primary outcome was incident AVD over long-term follow-up. Cox proportional hazards models adjusted for demographic and cardiovascular risk factors were used, supplemented by restricted cubic spline and age-stratified analyses. A total of 593 cases of AVD occurred among 11,905 participants during follow-up. IFG (hazard ratio 1.28, 95% confidence interval: 1.03–1.59) and diagnosed diabetes (hazard ratio 1.61, 95% confidence interval: 1.18–2.19) were significantly associated with increased risk. Spline analysis revealed a threshold effect above 5.5 mmol/L. Case–control comparisons showed persistently higher baseline glucose in cases. Kaplan–Meier curves demonstrated lowest event-free survival in diabetes and IFG groups. Even modest elevations in fasting glucose are associated with a significantly increased risk of AVD.
- Open Access
- 17 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104  (42) , e45315
Advances in endoscopic techniques for early detection and treatment of gastrointestinal cancers: A systematic review
Background: The early detection and treatment of gastrointestinal cancers are critical for improving patient outcomes. These techniques include white light endoscopy (WLE), chromoendoscopy, i-scan, flexible spectral imaging color enhancement (FICE), Narrow-Band Imaging (NBI), confocal laser endomicroscopy (CLE), and others. While these modalities offer promising diagnostic accuracy, their effectiveness varies based on the clinical setting and specific type of lesion. This systematic review aims to assess the diagnostic accuracy and clinical utility of these advanced endoscopic techniques in the early detection of gastrointestinal cancers. Methods: A comprehensive systematic review was conducted to evaluate studies published between January 2020 and December 2024. The inclusion criteria involved randomized controlled trials, prospective studies, and retrospective studies that compared advanced endoscopic techniques such as WLE, chromoendoscopy, i-scan, FICE, NBI, and CLE in the diagnosis of gastrointestinal cancers. Data on diagnostic accuracy, sensitivity, specificity, and clinical outcomes were extracted and analyzed. Studies were assessed for quality, and a comparison table was created to summarize key findings. Results: A total of 23 studies met the inclusion criteria, involving a diverse range of gastrointestinal cancers including colorectal, gastric, and esophageal cancers. The results showed that advanced endoscopic techniques, particularly NBI, FICE, and CLE, had significantly higher diagnostic accuracy compared to traditional WLE. For instance, NBI demonstrated superior accuracy in diagnosing colorectal and gastric lesions, while FICE was particularly effective in detecting gastric lesions. CLE showed high sensitivity and accuracy for detecting submucosal lesions. The diagnostic performance of i-scan and chromoendoscopy was also found to be promising, with several studies reporting improved detection rates in colorectal and gastric cancers. Conclusion: Advanced endoscopic techniques offer substantial improvements in the early detection and diagnosis of gastrointestinal cancers. NBI, FICE, CLE, and i-scan are among the most effective modalities, with superior diagnostic accuracy compared to traditional methods like WLE. However, challenges such as high costs, the need for specialized training, and the lack of large-scale clinical trials hinder their widespread adoption. Future research should focus on the integration of artificial intelligence, the development of cost-effective devices, and the standardization of protocols to enhance the utility of these technologies in clinical practice.
- 17 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104  (42) , e45315
Open AccessAdvances in endoscopic techniques for early detection and treatment of gastrointestinal cancers: A systematic review
Background: The early detection and treatment of gastrointestinal cancers are critical for improving patient outcomes. These techniques include white light endoscopy (WLE), chromoendoscopy, i-scan, flexible spectral imaging color enhancement (FICE), Narrow-Band Imaging (NBI), confocal laser endomicroscopy (CLE), and others. While these modalities offer promising diagnostic accuracy, their effectiveness varies based on the clinical setting and specific type of lesion. This systematic review aims to assess the diagnostic accuracy and clinical utility of these advanced endoscopic techniques in the early detection of gastrointestinal cancers. Methods: A comprehensive systematic review was conducted to evaluate studies published between January 2020 and December 2024. The inclusion criteria involved randomized controlled trials, prospective studies, and retrospective studies that compared advanced endoscopic techniques such as WLE, chromoendoscopy, i-scan, FICE, NBI, and CLE in the diagnosis of gastrointestinal cancers. Data on diagnostic accuracy, sensitivity, specificity, and clinical outcomes were extracted and analyzed. Studies were assessed for quality, and a comparison table was created to summarize key findings. Results: A total of 23 studies met the inclusion criteria, involving a diverse range of gastrointestinal cancers including colorectal, gastric, and esophageal cancers. The results showed that advanced endoscopic techniques, particularly NBI, FICE, and CLE, had significantly higher diagnostic accuracy compared to traditional WLE. For instance, NBI demonstrated superior accuracy in diagnosing colorectal and gastric lesions, while FICE was particularly effective in detecting gastric lesions. CLE showed high sensitivity and accuracy for detecting submucosal lesions. The diagnostic performance of i-scan and chromoendoscopy was also found to be promising, with several studies reporting improved detection rates in colorectal and gastric cancers. Conclusion: Advanced endoscopic techniques offer substantial improvements in the early detection and diagnosis of gastrointestinal cancers. NBI, FICE, CLE, and i-scan are among the most effective modalities, with superior diagnostic accuracy compared to traditional methods like WLE. However, challenges such as high costs, the need for specialized training, and the lack of large-scale clinical trials hinder their widespread adoption. Future research should focus on the integration of artificial intelligence, the development of cost-effective devices, and the standardization of protocols to enhance the utility of these technologies in clinical practice.
- Open Access
- 17 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104  (42) , e45259
Emerging biological therapies for psoriatic arthritis: A systematic review
Background: Psoriatic arthritis (PsA) is a chronic inflammatory condition characterized by joint involvement, enthesitis, dactylitis, and skin psoriasis. The pathophysiology of PsA is complex, driven by dysregulated immune responses, making targeted therapies essential for managing symptoms. Despite the success of biologic disease-modifying anti-rheumatic drugs (bDMARDs) like tumor necrosis factor (TNF) inhibitors, many patients experience suboptimal responses or adverse effects, necessitating the development of new therapies. Emerging biologics targeting interleukin (IL)-17, IL-23, and Janus kinase (JAK) pathways offer promising alternatives. This review aims to evaluate the efficacy and safety of emerging biologics for PsA. Methods: A systematic review of studies published from 2000 to December 2024 was conducted. Randomized controlled trials (RCTs), cohort studies, and clinical trials were included to assess the efficacy, safety, and adverse effects of bDMARDs and targeted synthetic DMARDs (tsDMARDs) for PsA treatment. Studies focusing on other aspects of psoriasis or nonpharmacological treatments were excluded. Key data extracted included study design, treatment type, efficacy measures (e.g., ACR response), and safety outcomes. Results: A total of 20 studies involving 77,124 participants were reviewed. Biologic DMARDs such as TNF inhibitors, IL-17 inhibitors (e.g., secukinumab, ixekizumab), and IL-23 inhibitors (e.g., guselkumab) showed high efficacy in managing both joint and skin symptoms. Emerging therapies like bimekizumab (targeting IL-17A and IL-17F) demonstrated enhanced efficacy compared to traditional biologics. Conventional DMARDs, such as cyclosporine and leflunomide, were less effective but still showed moderate benefits. Safety profiles were generally favorable, with biologics showing fewer adverse effects than conventional therapies. Conclusion: Emerging biologics have significantly advanced the management of PsA, offering greater efficacy and safety compared to conventional DMARDs. IL-17 and IL-23 inhibitors, along with newer agents like bimekizumab, present promising treatment options for patients with inadequate responses to TNF inhibitors. Personalized treatment strategies, based on disease phenotype and individual patient needs, are essential for optimizing outcomes in PsA management. Further research into long-term efficacy and safety is required to refine treatment protocols and improve patient outcomes.
- 17 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104  (42) , e45259
Open AccessEmerging biological therapies for psoriatic arthritis: A systematic review
Background: Psoriatic arthritis (PsA) is a chronic inflammatory condition characterized by joint involvement, enthesitis, dactylitis, and skin psoriasis. The pathophysiology of PsA is complex, driven by dysregulated immune responses, making targeted therapies essential for managing symptoms. Despite the success of biologic disease-modifying anti-rheumatic drugs (bDMARDs) like tumor necrosis factor (TNF) inhibitors, many patients experience suboptimal responses or adverse effects, necessitating the development of new therapies. Emerging biologics targeting interleukin (IL)-17, IL-23, and Janus kinase (JAK) pathways offer promising alternatives. This review aims to evaluate the efficacy and safety of emerging biologics for PsA. Methods: A systematic review of studies published from 2000 to December 2024 was conducted. Randomized controlled trials (RCTs), cohort studies, and clinical trials were included to assess the efficacy, safety, and adverse effects of bDMARDs and targeted synthetic DMARDs (tsDMARDs) for PsA treatment. Studies focusing on other aspects of psoriasis or nonpharmacological treatments were excluded. Key data extracted included study design, treatment type, efficacy measures (e.g., ACR response), and safety outcomes. Results: A total of 20 studies involving 77,124 participants were reviewed. Biologic DMARDs such as TNF inhibitors, IL-17 inhibitors (e.g., secukinumab, ixekizumab), and IL-23 inhibitors (e.g., guselkumab) showed high efficacy in managing both joint and skin symptoms. Emerging therapies like bimekizumab (targeting IL-17A and IL-17F) demonstrated enhanced efficacy compared to traditional biologics. Conventional DMARDs, such as cyclosporine and leflunomide, were less effective but still showed moderate benefits. Safety profiles were generally favorable, with biologics showing fewer adverse effects than conventional therapies. Conclusion: Emerging biologics have significantly advanced the management of PsA, offering greater efficacy and safety compared to conventional DMARDs. IL-17 and IL-23 inhibitors, along with newer agents like bimekizumab, present promising treatment options for patients with inadequate responses to TNF inhibitors. Personalized treatment strategies, based on disease phenotype and individual patient needs, are essential for optimizing outcomes in PsA management. Further research into long-term efficacy and safety is required to refine treatment protocols and improve patient outcomes.